Related Experiment Video
Updated: Feb 22, 2026
Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
Published on: November 5, 2016
Stem cell biology and regenerative medicine for neonatal lung diseases
Martin Kang1, Bernard Thébaud2
1Ottawa Hospital Research Institute, Sinclair Centre for Regenerative Medicine, Ottawa, Ontario, Canada.
Insights
Cell therapy shows promise for treating neonatal lung diseases. Stem cells like mesenchymal stromal cells and induced pluripotent stem cells offer potential for conditions such as bronchopulmonary dysplasia and surfactant protein deficiencies.
Area of Science:
- Regenerative medicine
- Neonatal lung disease research
Background:
- Neonatal lung diseases are a major cause of infant mortality.
- Current treatments for severe neonatal lung conditions are limited.
- Cell and regenerative medicine offer novel therapeutic avenues.
Purpose of the Study:
- To review the potential of stem/progenitor cells in treating experimental neonatal lung diseases.
- To highlight specific cell types and their applications in neonatal lung disorders.
- To discuss the progress and challenges in clinical translation of cell therapies.
Main Methods:
- Review of experimental studies on stem/progenitor cell therapies for neonatal lung injury.
- Focus on mesenchymal stromal cells, amnion epithelial cells, endothelial progenitor cells, and induced pluripotent stem cells (iPSCs).
- Discussion of cell differentiation and therapeutic applications for specific neonatal lung conditions.
Main Results:
- Mesenchymal stromal cells and amnion epithelial cells show therapeutic potential for bronchopulmonary dysplasia.
- Endothelial progenitor cells can promote vascular growth and reduce pulmonary hypertension.
- Patient-specific iPSCs offer a pathway for personalized cell replacement therapies for genetic lung disorders.
Conclusions:
- Cell therapy holds significant promise for revolutionizing the management of neonatal lung diseases.
- Further research into the biology of repair cells is crucial for successful clinical translation.
- Personalized regenerative medicine approaches using iPSCs are emerging for specific genetic lung conditions.
Abstract:
Lung diseases remain one of the main causes of morbidity and mortality in neonates. Cell therapy and regenerative medicine have the potential to revolutionize the management of life-threatening and debilitating lung diseases that currently lack effective treatments. Over the past decade, the repair capabilities of stem/progenitor cells have been harnessed to prevent/rescue lung damage in experimental neonatal lung diseases. Mesenchymal stromal cells and amnion epithelial cells exert pleiotropic effects and represent ideal therapeutic cells for bronchopulmonary dysplasia, a multifactorial disease. Endothelial progenitor cells are optimally suited to promote lung vascular growth and attenuate pulmonary hypertension in infants with congenital diaphragmatic hernia or a vascular bronchopulmonary dysplasia phenotype. Induced pluripotent stem cells (iPSCs) are one of the most exciting breakthroughs of the past decade. Patient-specific iPSCs can be derived from somatic cells and differentiated into any cell type. iPSCs can be capitalized upon to develop personalized regenerative cell products for surfactant protein deficiencies-lethal lung disorders without treatment-that affect a single gene in a single cell type and thus lend themselves to phenotype-specific cell replacement. While the clinical translation has begun, more needs to be learned about the biology of these repair cells to make this translation successful.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:17Stem Cell Culture
01:22iPS Cell Differentiation
00:58Embryonic Stem Cells
00:57Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...